Researchers from the University of Glasgow revealed that the screening and treating middle-aged adults with a family history of coronary heart disease could prevent more than 4 in 10 premature heart attacks.
The U.S. Food and Drug Administration today approved the first generic versions of Coreg (carvedilol). Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to severe chronic heart failure and left ventricular dysfunction following a heart attack.
Screening and treating middle-aged adults with a family history of coronary heart disease could prevent more than 4 in 10 premature heart attacks, according to an article in this week?s BMJ.
Soluble fiber ? from beans, some fruits and even coffee ? may help lower low-density lipoprotein (LDL) or “bad” cholesterol and blood sugar and may help protect against heart attack and stroke.
In a national study of more than 8 million hospitalized Medicare patients, there was no increase in mortality in the first two years following duty hour reform that limited work hours for resident physicians, according to an article in the Sept. 5 issue of JAMA, a theme issue on medical education.
Drug-coated stents were linked to a higher death rate when given to people who’ve had massive heart attacks, revealed by researchers in a study performed in Sweden.
Patients with depression appear to have an impaired ability to recover their heart rate variability following acute coronary syndromes such as heart attack, a factor that could increase their risk of coronary death, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Two new studies led by researchers at the University of Iowa and the Department of Veterans Affairs Iowa City Health Care System provide reassuring findings for patients evaluated in the emergency room for possible acute coronary syndrome (ACS) and the physicians who treat them.
Sleep disorder and ear, nose and throat specialists at Thomas Jefferson University are examining an innovative procedure to treat obstructive sleep apnea syndrome.
Geron Corporation (Nasdaq: GERN) today reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.